Embecta investors face Aug. 17 deadline in securities suit notice
A law firm said Embecta Corp. investors who lost money may ask a court to appoint them lead plaintiff in a securities fraud class action, with a motion deadline of Aug. 17, 2026.
A law firm said Embecta Corp. investors who lost money may ask a court to appoint them lead plaintiff in a securities fraud class action, with a motion deadline of Aug. 17, 2026.
Glancy Prongay Wolke & Rotter LLP said in a PR Newswire notice that investors who bought Embecta Corp. securities between Nov. 25, 2025, and May 4, 2026, may seek appointment as lead plaintiff in a securities fraud class action.
The notice says no class has been certified and that investors within the stated period may take no action and remain absent class members if they do not want to pursue that role.
According to the notice, the proposed class period runs from Nov. 25, 2025, through May 4, 2026. It says the complaint alleges defendants made materially false or misleading statements and failed to disclose adverse facts about Embecta’s business, operations and prospects.
The notice lists three alleged nondisclosures. It says the company’s guidance was misleading and unattainable. It also says weakness in the company’s segments, especially in the U.S. pen needle market, was likely to disrupt original revenue guidance and second-quarter 2026 results. The release says the defendants’ positive statements lacked a reasonable basis.
The notice does not include Embecta’s response. The source is a litigation solicitation distributed through PR Newswire, so the allegations are claims in a pending case, not findings of fact.
PR Newswire published the notice on Aug. 11, 2026, and the release says any investor who wants to serve as lead plaintiff must move the court no later than Aug. 17, 2026.
The notice also says the firm provided contact information, including an email address and telephone numbers, for investors seeking more information.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.